Sandler et al published their results with paclitaxel (Taxol), carboplatin, and bevacizumab (Avastin) versus paclitaxel/carboplatin alone in New England Journal of Medicine 355 (24): 2542-50, 2006.
Here were the results:
Chances of response by adding Avastin increased from 15 to 35%
Median (not average) survival increased from 10.3 to 12.3 months
Multiple studies with chemo have been done, usually using two drugs and one being cisplatin/carboplatin. Frequent median survivals run 10-12 months. An average benefit is that taking chemotherapy may give a patient about a 5-10% better chance of being alive one year later.
Obviously these benefits are not huge, and this treatment is not for everyone. "Healthier" patients do better, as do better performance status patients, younger ones, those who don’t smoke, etc.
One comment
zrepmd on June 1, 2011 at 2:11 pm
Sandler et al published their results with paclitaxel (Taxol), carboplatin, and bevacizumab (Avastin) versus paclitaxel/carboplatin alone in New England Journal of Medicine 355 (24): 2542-50, 2006.
Here were the results:
Chances of response by adding Avastin increased from 15 to 35%
Median (not average) survival increased from 10.3 to 12.3 months
Multiple studies with chemo have been done, usually using two drugs and one being cisplatin/carboplatin. Frequent median survivals run 10-12 months. An average benefit is that taking chemotherapy may give a patient about a 5-10% better chance of being alive one year later.
Obviously these benefits are not huge, and this treatment is not for everyone. "Healthier" patients do better, as do better performance status patients, younger ones, those who don’t smoke, etc.
Blessings